{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:25:33Z","timestamp":1747977933340,"version":"3.41.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002507","name":"Kangwon National University","doi-asserted-by":"publisher","award":["202202500001"],"award-info":[{"award-number":["202202500001"]}],"id":[{"id":"10.13039\/501100002507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["NRF-2018R1A1A3A04076879"],"award-info":[{"award-number":["NRF-2018R1A1A3A04076879"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clbc.2024.12.007","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T15:13:13Z","timestamp":1733757193000},"page":"335-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Menopausal Symptom Burden in Premenopausal Breast Cancer Patients: Interaction of Chemotherapy and Ovarian Function Suppression on Tamoxifen Treatment"],"prefix":"10.1016","volume":"25","author":[{"given":"Young-Won","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seunghee","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Kyung Robyn","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jisun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Il Yong","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beom Seok","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Ho","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae Byul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1657-8582","authenticated-orcid":false,"given":"Yul Ha","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clbc.2024.12.007_bib0001","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1055\/s-0042-106389","article-title":"Significance of ovarian function suppression in endocrine therapy for breast cancer in pre-menopausal women","volume":"76","author":"Scharl","year":"2016","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.007_bib0002","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clbc.2024.12.007_bib0003","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.22.01065","article-title":"Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT","volume":"41","author":"Francis","year":"2023","journal-title":"J Clin Oncol"},{"year":"2023","series-title":"Version 4. NCCN","key":"10.1016\/j.clbc.2024.12.007_bib0004"},{"issue":"4","key":"10.1016\/j.clbc.2024.12.007_bib0005","article-title":"LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women","volume":"2009","author":"Goel","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.clbc.2024.12.007_bib0006","doi-asserted-by":"crossref","first-page":"e654","DOI":"10.1016\/j.clbc.2019.06.003","article-title":"Effectiveness of adjuvant ovarian function suppression in premenopausal women with early breast cancer: a multicenter cohort study","volume":"19","author":"Ferreira","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.007_bib0007","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-006-9260-6","article-title":"Quality of life of postmenopausal women in the ATAC (\"Arimidex\", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer","volume":"100","author":"Cella","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2024.12.007_bib0008","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.breast.2020.10.015","article-title":"Tamoxifen related side effects and their impact on breast cancer incidence: a retrospective analysis of the randomised IBIS-I trial","volume":"54","author":"Hale","year":"2020","journal-title":"Breast"},{"issue":"35","key":"10.1016\/j.clbc.2024.12.007_bib0009","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2014.55.6993","article-title":"Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group","volume":"32","author":"Tevaarwerk","year":"2014","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clbc.2024.12.007_bib0010","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","article-title":"Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial","volume":"34","author":"Ribi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clbc.2024.12.007_bib0011","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.bjc.6604758","article-title":"Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer","volume":"99","author":"McCowan","year":"2008","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.007_bib0012","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3390\/curroncol30020112","article-title":"Adherence to adjuvant endocrine therapy in breast cancer patients","volume":"30","author":"Rosso","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clbc.2024.12.007_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.844926","article-title":"Hot flushes and sweating, sleep problems, joint and muscular discomfort, and physical and mental exhaustion in breast cancer survivors during the first 24 months of tamoxifen therapy: a prospective observational study","volume":"12","author":"Sung","year":"2022","journal-title":"Front Oncol"},{"issue":"27","key":"10.1016\/j.clbc.2024.12.007_bib0014","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","article-title":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients","volume":"28","author":"Hershman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.clbc.2024.12.007_bib0015","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1200\/JCO.2007.10.8274","article-title":"Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy","volume":"25","author":"Jones","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2024.12.007_bib0016","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3346\/jkms.2010.25.5.758","article-title":"Factors influencing the severity of menopause symptoms in Korean post-menopausal women","volume":"25","author":"Lee","year":"2010","journal-title":"J Korean Med Sci"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.007_bib0017","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/0167482X.2016.1216963","article-title":"Factors related to the experience of menopausal symptoms in women prescribed tamoxifen","volume":"38","author":"Moon","year":"2017","journal-title":"J Psychosom Obstet Gynaecol"},{"issue":"10","key":"10.1016\/j.clbc.2024.12.007_bib0018","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/GME.0000000000000219","article-title":"Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis","volume":"21","author":"Davis","year":"2014","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.clbc.2024.12.007_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000562","article-title":"UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)","volume":"4","author":"Vaz-Luis","year":"2019","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.clbc.2024.12.007_bib0020","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/sj.bjc.6600294","article-title":"Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy","volume":"86","author":"Mourits","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2024.12.007_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/1179554920931816","article-title":"Current state of the art in the adjuvant systemic treatment of premenopausal patients with early breast cancer","volume":"14","author":"Parisi","year":"2020","journal-title":"Clin Med Insights Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.007_bib0022","article-title":"Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer","volume":"3","author":"Bui","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"27","key":"10.1016\/j.clbc.2024.12.007_bib0023","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2016.72.0946","article-title":"Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials","volume":"35","author":"Saha","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2024.12.007_bib0024","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","article-title":"Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials","volume":"16","author":"Bernhard","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2024.12.007_bib0025","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0959-8049(03)00392-7","article-title":"Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer","volume":"39","author":"Kaufmann","year":"2003","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.clbc.2024.12.007_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.43910","article-title":"Chemotherapy-related amenorrhea and quality of life among premenopausal women with breast cancer","volume":"6","author":"Kabirian","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.007_bib0027","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.fertnstert.2015.11.020","article-title":"Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all","volume":"105","author":"Jacobson","year":"2016","journal-title":"Fertil Steril"},{"issue":"19","key":"10.1016\/j.clbc.2024.12.007_bib0028","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","article-title":"Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data","volume":"36","author":"Lambertini","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.007_bib0029","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/EDBK_350358","article-title":"Personalizing adjuvant endocrine therapy for early-stage hormone receptor\u2013positive breast cancer","volume":"42","author":"Pistilli","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.007_bib0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11864-017-0442-8","article-title":"Ovarian function suppression in premenopausal women with early-stage breast cancer","volume":"18","author":"Lambertini","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.007_bib0031","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10549-021-06368-4","article-title":"Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer","volume":"190","author":"Sukumar","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.clbc.2024.12.007_bib0032","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1200\/JCO.2003.04.024","article-title":"Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study","volume":"21","author":"Nystedt","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924003549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924003549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T01:19:52Z","timestamp":1747963192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924003549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1526820924003549"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.12.007","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Menopausal Symptom Burden in Premenopausal Breast Cancer Patients: Interaction of Chemotherapy and Ovarian Function Suppression on Tamoxifen Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}